The primary objective of this study is to describe the response to treatment with biosimilar EPO alpha in MDS patients who had already been treated with "originator" EPO alpha and were responsive, and in patients who started treatment with biosimilar EPO alpha
Age ≥ 18 years at the time of enrollment
Acquisition of informed consent to study participation and data processing
- Presence of other possible contributory causes of anemia (e.g., anemia from chronic inflammatory disease, hemolysis, hemorrhage)
Poor compliance with treatment
Very impaired general clinical condition (ECOG performance status > 3)
Concomitant treatment with antineoplastic cytotoxic drugs